Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16014245 | 0.85 | HDAC3 (0.48) | MAPTRAPGEF4ALOX5 | |
| SCHEMBL11080475 | 0.81 | MEN1 (0.53) | MAPTSTK17AGAAMEN1KMT2A | |
| SCHEMBL11078558 | 0.77 | POLA1 (0.50) | STK17ARAPGEF4 | |
| SCHEMBL17403482 | 0.73 | MAPT (0.52) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL16023771 | 0.73 | MAPT (0.46) | MAPTSTK17AMEN1KMT2ARAPGEF4 | |
| SCHEMBL11089778 | 0.70 | SMN1; SMN2 (0.53) | MAPTGAAMEN1KMT2A | |
| SCHEMBL8524268 | 0.70 | MAPT (0.51) | MAPTMEN1KMT2AADORA3SLC6A2 | |
| SCHEMBL11088916 | 0.70 | RAB9A (0.53) | MAPTGAAMEN1KMT2A | |
| SCHEMBL23643491 | 0.70 | NFKB1 (0.57) | MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL11083592 | 0.69 | HDAC3 (0.40) | MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | claimed |
| EP-2964620-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | claimed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | claimed |
| WO-2014135423-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | claimed |
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2964620-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| WO-2014135423-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135423-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HAVCR2, UGT1A1, UGT1A3 | MAPT 4404/4885STK17A 3983/4885GAA 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.